AGIO - NASDAQ
Agios Pharmaceuticals, Inc.
$27.68
-1.1%Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAgios Pharmaceuticals, Inc. Management Team
Ms. Tsveta Milanova
Chief Commercial Officer
Compensation
$836,643
Mr. Brian M. Goff M.B.A.
Chief Executive Officer & Director
Compensation
$1,553,274
Ms. Cecilia Jones
Chief Financial Officer
Compensation
$802,574
Dr. Sarah Gheuens M.D., Ph.D.
Chief Medical Officer and Head of Research & Development
Compensation
$927,572
Dr. Craig B. Thompson M.D.
Co-Founder
Dr. Lewis clayton Cantley Ph.D.
Co-Founder
Compensation
$50,000
Dr. Shin-San Su Ph.D.
Co-Founder
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.
Co-Founder
Mr. James William Burns
Corporate Secretary & Chief Legal Officer
Compensation
$815,732
Mr. T. J. Washburn
Vice President, Controller & Principal Accounting Officer
Agios Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $5K and sold $1.62M worth of AGIO shares, resulting in $1.61M of net selling activity.
3 Months
0
0.00
22.2K
769.80K
-770K
-$770K
3-6 Months
0
0.00
26.2K
731.70K
-732K
-$732K
6-9 Months
200
5.00K
2.7K
116.20K
-111K
-$111K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Gheuens Sarah
Officer: Chief Medical Officer
$5K
Top Sellers
Goff Brian
Director, Officer: Chief Executive Officer
$569K
Gheuens Sarah
Officer: Chief Medical Officer
$209K
Burns James William
Officer: Chief Legal Officer
$193K
Milanova Tsveta
Officer: Chief Commercial Officer
$191K
Viswanadhan Krishnan
Officer: Chief Corp Dev & Strategy
$185K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.61M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
AGIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 18, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 26, 2023 | April 26, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 21, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 08, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 16, 2020 | May 28, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 18, 2019 | May 29, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 18, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 24, 2017 | June 13, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.